Janux Therapeutics (JANX) vs Vericel (VCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vericel (VCEL) has outperformed Janux Therapeutics (JANX) over the past year, gaining 17.3% versus a loss of 23.6%. Over five years, JANX leads with a -12.4% price change compared with -21.1% for VCEL. Vericel is the larger company by market cap ($2.05 billion vs $1.13 billion), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JANX | VCEL |
|---|---|---|
| Share price | $18.50 | $40.05 |
| Market cap | $1.13B | $2.05B |
| 1-day change | +3.24% | -1.69% |
| YTD return | +34.06% | +11.22% |
| 1-year return | -23.55% | +17.35% |
| 5-year return | -12.45% | -21.15% |
| P/E ratio (TTM) | — | 85.21 |
| Forward P/E | — | 47.34 |
| EPS (TTM) | $-1.64 | $0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $276.26M |
| Revenue growth (YoY) | — | +16.45% |
| Net income (latest FY) | — | $16.52M |
| Gross margin | — | 74.42% |
| Operating margin | — | 4.00% |
| Net margin | — | 5.98% |
| 52-week high | $35.34 | $49.32 |
| 52-week low | $12.12 | $28.95 |
| Distance from 52-week high | -47.65% | -18.80% |
| Analyst consensus | none | none |
| Avg. price target upside | +95.89% | +51.24% |
| Average volume | 845.95K | 502.23K |
| Shares outstanding | 61.14M | 51.21M |
| Employees | 113 | 398 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VCEL has outperformed JANX by 40.9 percentage points over the past year.
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Healthcare · Biotechnology · 113 employees
About Vericel
VCEL stock →Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Healthcare · Biotechnology · 398 employees
JANX vs VCEL FAQ
Which is bigger, Janux Therapeutics or Vericel?
Vericel (VCEL) is larger, with a market capitalization of $2.05B compared with $1.13B for Janux Therapeutics (JANX).
Which stock has performed better over the past year, JANX or VCEL?
VCEL returned +17.35% over the past 12 months, compared with -23.55% for JANX (price return, excluding dividends). Past performance does not predict future results.
Are Janux Therapeutics and Vericel in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.